
Biogen BIIB
€ 168.27
2.35%
Quartalsbericht 2026-Q1
hinzugefügt 29.04.2026
Biogen Betriebsaufwand 2011-2026 | BIIB
Betriebsaufwand Jährlich Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 5.39 B | 5.64 B | 5.12 B | 4.32 B | 4.51 B | 4.62 B | 3.58 B | 3.13 B | 2.84 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.64 B | 2.84 B | 4.35 B |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.14 | 0.74 % | $ 895 M | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 14.74 | -0.2 % | $ 216 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.63 | 3.5 % | $ 434 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 94.9 | 0.82 % | $ 22.9 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | -0.48 % | $ 651 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | ||
|
Exelixis
EXEL
|
598 M | $ 49.35 | 2.47 % | $ 13.4 B | ||
|
Fortress Biotech
FBIO
|
125 M | $ 2.36 | -1.26 % | $ 65.8 M | ||
|
Forte Biosciences
FBRX
|
70.7 M | $ 24.9 | 3.65 % | $ 322 M | ||
|
AbbVie
ABBV
|
12.8 B | $ 203.32 | 0.97 % | $ 360 B | ||
|
Gilead Sciences
GILD
|
13.5 B | $ 133.2 | 1.42 % | $ 166 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Compugen Ltd.
CGEN
|
40.4 M | $ 2.82 | -2.76 % | $ 263 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 0.77 | 0.16 % | $ 35.2 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.41 | 0.04 % | $ 3.71 B | ||
|
Genprex
GNPX
|
18 M | $ 0.85 | -1.99 % | $ 793 K | ||
|
Genmab A/S
GMAB
|
67.9 M | $ 26.36 | -0.26 % | $ 1.71 B | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.46 | -1.98 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.05 | -0.62 % | $ 5.47 B | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.09 | -0.4 % | $ 2.68 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M |